{"id":415986,"date":"2024-10-20T06:08:17","date_gmt":"2024-10-20T06:08:17","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/bs-en-iso-16638-22022\/"},"modified":"2024-10-26T11:24:20","modified_gmt":"2024-10-26T11:24:20","slug":"bs-en-iso-16638-22022","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/bsi\/bs-en-iso-16638-22022\/","title":{"rendered":"BS EN ISO 16638-2:2022"},"content":{"rendered":"
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
2<\/td>\n | undefined <\/td>\n<\/tr>\n | ||||||
4<\/td>\n | European foreword Endorsement notice <\/td>\n<\/tr>\n | ||||||
5<\/td>\n | \u200b Annex G (informative) A-deviations <\/td>\n<\/tr>\n | ||||||
6<\/td>\n | Blank Page <\/td>\n<\/tr>\n | ||||||
8<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
9<\/td>\n | Introduction <\/td>\n<\/tr>\n | ||||||
11<\/td>\n | 1 Scope <\/td>\n<\/tr>\n | ||||||
12<\/td>\n | 2 Normative references 3 Terms and definitions <\/td>\n<\/tr>\n | ||||||
14<\/td>\n | 4 Symbols and abbreviated terms 4.1 Symbols <\/td>\n<\/tr>\n | ||||||
15<\/td>\n | 4.2 Abbreviated terms 5 Purpose and need for monitoring programmes <\/td>\n<\/tr>\n | ||||||
17<\/td>\n | 6 General aspects <\/td>\n<\/tr>\n | ||||||
18<\/td>\n | 7 Special monitoring programmes 8 Task-related monitoring programmes for individual monitoring 9 Reference values as performance criteria for laboratories <\/td>\n<\/tr>\n | ||||||
19<\/td>\n | 10 Quality assurance and quality control for bioassay laboratories <\/td>\n<\/tr>\n | ||||||
20<\/td>\n | 11 Procedure for the assessment of exposures 11.1 \u200bAssessment of individual monitoring data 11.2 Properties of a software tool <\/td>\n<\/tr>\n | ||||||
21<\/td>\n | 11.3 Uncertainties 11.4 Quality assurance of the assessment process <\/td>\n<\/tr>\n | ||||||
22<\/td>\n | 12 Reporting and documentation 12.1 Reporting results for in vitro measurements 12.2 Documentation of the dose assessment <\/td>\n<\/tr>\n | ||||||
24<\/td>\n | Annex A (informative) Nuclear data of U-238 and U-235 decay <\/td>\n<\/tr>\n | ||||||
25<\/td>\n | Annex B (informative) Default classification of uranium compounds <\/td>\n<\/tr>\n | ||||||
26<\/td>\n | Annex C (informative) Measurement techniques for uranium in case of ingestion <\/td>\n<\/tr>\n | ||||||
29<\/td>\n | Annex D (informative) Excretion rates for ingestion of uranium compounds <\/td>\n<\/tr>\n | ||||||
31<\/td>\n | Annex E (informative) Committed effective dose per unit intake after ingestion of uranium compounds <\/td>\n<\/tr>\n | ||||||
32<\/td>\n | Annex F (informative) Estimation of uncertainties for internal dose assessments after ingestion <\/td>\n<\/tr>\n | ||||||
35<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" Radiological protection. Monitoring and internal dosimetry for specific materials – Ingestion of uranium compounds<\/b><\/p>\n |